Search PubMed⌕ Search

Biomedical subjects

G M Besser

Publications and source records attributed to G M Besser.

At least 505 records · Page 28Linked to original sources
PubMed1973

Luteinizing hormone and follicle stimulating hormone-releasing hormone test in patients with hypothalamic-pituitary-gonadal dysfunction.

A standard intravenous 100 mug luteinizing hormone/follicle stimulating hormone-releasing hormone (LH/FSH-RH) test was used to assess the pituitary gonadotrophin responses in 155 patients with a variety of diseases of the hypothalamic-pituitary-gonadal axis. In all but nine patients there was an increase in circulating levels of either LH or FSH in response to the releasing hormone though 137 (88%) were clinically hypogonadal. It was not possible with this test to distinguish between hypothalamic and pituitary causes of hypogonadotrophic hypogonadism, since a variety of LH and FSH responses emerged within the disease groups. However, primary gonadal failure characteristically resulted in exaggerated gonadotrophin response. The potential therapeutic use of the gonadotrophin releasing decapeptide is suggested in certain patients with hypogonadotrophic hypogonadism.

Adolescent↗
PubMed1973

Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies.

In seven patients with cranial diabetes insipidus an analogue of vasopressin, DDAVP, produced an antidiuresis lasting up to 20 hours after a single intranasal dose. Lysine vasopressin (LVP) in the same dose produced a less potent antidiuresis which lasted for only three to four hours. The plasma half life of DDAVP was 7.8 and 75.5 min for the fast and slow phases, compared with 2.5 and 14.5 min for LVP. Radioiodine-labelled DDAVP was not destroyed by incubation with late pregnancy plasma, which contains an enzyme that inactivates vasopressin. The slow metabolic clearance of DDAVP, its absorption through the nasal mucosa, and its lack of side effects make this the ideal drug for the treatment of vasopressin-sensitive diabetes insipidus. Patients usually require 10 to 20 mug DDAVP given intranasally twice daily for good clinical control of their diabetes insipidus.

Adolescent↗
PubMed1972

Effects of oestrogen on urinary thyrosine excretion.

The day to day variation and the effects of oestrogen on the urinary excretion of thyroxine (T-4) were studied in euthyroid women and men. Serial urinary T-4 values over a period of 28 consecutive days were found to lie within relatively narrow limits except for a transient increase during menstruation in women. During oestrogen therapy urinary T-4 was unchanged, but an appreciable rise was seen after stopping oral ovulation inhibitors in women. A similar effect was seen in men after three days' treatment with 20 mug/day of ethinyloestradiol. The increased urinary T-4 excretion on oestrogen withdrawal reached a maximum in one to three days. This response contrasted with that produced by phenytoin, a drug known to bind to thyroxine binding globulin, and which resulted in increased urinary T-4 excretion during the period that it was being administered.

Adult↗
PubMed1972

Isolated pituitary gonadotrophin deficiency: gonadotrophin secretion after synthetic luteinizing hormone and follicle stimulation hormone-releasing hormone.

The responses of serum immunoreactive luteinizing hormone (LH) and follicle stimulating hormone (FSH) after intravenous injection of 100 mug of synthetic LH/FSH-RH have been studied in 14 patients with the syndrome of isolated pituitary gonadotrophin deficiency. Nine of the patients showed a rise of both hormones, two a small rise of FSH only, and three were unresponsive. In two of the unresponsive patients injection of a 500-mug dose produced a small rise of LH only. Of the patients who responded, four had LH and FSH responses within the normal adult range, while in the others the responses were smaller and delayed. It is suggested that this syndrome is due to a lack of the hypothalamic-releasing hormone itself, rather than to a pituitary deficiency. However, repeat assessment after prolonged administration of the releasing hormone will be necessary before a pituitary disorder can be excluded in all patients. The synthetic LH/FSH-RH, preferably as a depot preparation, may provide a means of treating these patients to induce the development of puberty and subsequent fertility.

Adolescent↗